Journal of Translational Medicine (Jul 2024)

Clinical implications of the family history in patients with lung cancer: a systematic review of the literature and a new cross-sectional/prospective study design (FAHIC: lung)

  • Fabrizio Citarella,
  • Kazuki Takada,
  • Priscilla Cascetta,
  • Pierfilippo Crucitti,
  • Roberta Petti,
  • Bruno Vincenzi,
  • Giuseppe Tonini,
  • Francesco M. Venanzi,
  • Alessandra Bulotta,
  • Sara Oresti,
  • Carlo Greco,
  • Sara Ramella,
  • Lucio Crinò,
  • Angelo Delmonte,
  • Roberto Ferrara,
  • Massimo Di Maio,
  • Fiorella Gurrieri,
  • Alessio Cortellini

DOI
https://doi.org/10.1186/s12967-024-05538-4
Journal volume & issue
Vol. 22, no. 1
pp. 1 – 32

Abstract

Read online

Abstract Compared to other malignancies, few studies have investigated the role of family history of cancer (FHC) in patients with lung cancer, yielding largely heterogeneous results. We performed a systematic literature review in accordance with PRISMA guidelines, searching the PubMed and Scopus databases from their inception to November 25, 2023, to identify studies reporting on the role of FHC in patients with lung cancer. A total of 53 articles were included, most with a retrospective design and encompassing a variety of geographical areas and ethnicities. Thirty studies (56.6%) assessed patients with non-small cell lung cancer (NSCLC), while 17 studies (32.1%) assessed patients with mixed histologies. Overall, the rates of FHC ranged from 8.3 to 68.9%, and the rates of family history of lung cancer ranged from 2 to 46.8%. Twenty-seven studies investigated FHC as a potential risk factor for lung cancer, with more than half reporting an increased risk for subjects with FHC. Five studies reported on the potential role of FHC in determining clinical outcomes, and twelve studies examined the relationship between FHC and germline mutations. Notably, only one study reported a significantly increased rate of germline mutations, including ATM, BRCA2, and TP53, for patients with a family history of lung cancer compared to those without, but both groups had a low prevalence of mutations (< 1%). The FAHIC—Lung (NCT06196424) is the first cross-sectional/prospective study specifically developed to identify FHC patterns and within-family clusters of other risk factors, including smoking, to guide patients with NSCLC to systematic genetic counseling. Acknowledging the largely heterogeneous results of our systematic review and considering the clinical implications of detecting pathogenic germline variants (PGVs), the FAHIC-lung study aims to identify patients potentially enriched with PGVs/likely PGVs to direct them to germline screening outside of the research setting.

Keywords